Checkpoint Therapeutics (CKPT) has agreed to be acquired by India's Sun Pharmaceutical Industries for $4.10 per share in cash plus a non-transferable contingent value right, the companies said Sunday.
The contingent value right entitles the stockholder to receive up to an additional $0.70 in cash if metastatic cutaneous squamous cell carcinoma treatment cosibelimab is approved before deadlines in the European Union or in certain countries, the companies said.
Checkpoint, its controlling shareholder Fortress Biotech (FBIO), and Sun Pharma have also entered into a royalty agreement under which Fortress will receive royalties from future sales of cosibelimab during a specified term.
The proposed transaction is expected to close in Q2, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。